Induction of androgen receptor by α,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells

Endocrinology

Volumn 140, Issue 3, 1999, Pages 1205-1212

  Zhao, Xiao Yan ^a   Ly, Lan H ^a   Peehl, Donna M ^a   Feldman, David ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANDROGEN RECEPTOR; CALCITRIOL;

ARTICLE; CALCIUM HOMEOSTASIS; CANCER CELL; CELL PROLIFERATION; GENE TARGETING; GROWTH INHIBITION; HORMONE RESPONSE; HUMAN; HUMAN CELL; MEDIATOR RELEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REPORTER GENE;

EID: 0032937372     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.3.6561     Document Type: Article

References (43)

1. 1. Feldman D, Malloy PJ, Gross C 1996 Vitamin D: metabolism and action. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 205-235
2. 2. Haussler MR, Whitfield GK, Haussier CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW 1998 The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325-349
3. 3. Walters MR 1992 Newly identified actions of the vitamin D endocrine system. Endocr Rev 13:719-764
4. 4. Bikle DD 1992 Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 13:765-784
5. 5. Gross C, Peehl DM, Feldman D 1997 Vitamin D and prostate cancer. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 1125-1140
6. 6. van Leeuwen JPTM, Pols HAP 1997 Vitamin D: Anticancer and differentiation. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 1089-1106
7. 7. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, O'Malley BW 1988 Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85:3294-3298
8. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960
9. 3. Endocrinology 136:20-26
10. 3. Cancer Res 52:515-520
11. 3 on primary cultures of human prostatic cells. Cancer Res 54:805-810
12. 3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997-1003
13. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277-288
14. 3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137:1554-1561
15. 15. Esquenet M, Swinnen JV, Heyns W, Verhoeven G 1996 Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28:182-194
16. 3 in androgen-responsive LNCaP cells. Biochem Biophys Res Commun 235:539-544
17. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138:1491-1497
18. 3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15-27
19. 19. Zhuang SH, Schwarte GG, Cameron D, Burnstein KL 1997 Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90
20. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197-1207
21. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-3298
22. 3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 223:141-146
23. 23. Mizokami A, Yeh SY, Chang C 1994 Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol 8:77-88
24. 24. Burton K 1956 A study of conditions and mechanisms of the diphenyl amine colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315-323
25. 25. Malloy PJ, Hochberg Z, Pike JW, Feldman D 1989 Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent ricketts, type II. J Clin Endocrinol Metab 68:263-269
26. 26. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254
27. 27. Zhao XY, Eccleshall TR, Krishnan AV, Gross C, Feldman D 1997 Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system. Mol Endocrinol 11:366-378
28. 28. Krishnan A, Feldman D 1997 Regulation of vitamin D receptor abundance. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, pp 179-200
29. 3 in cultured mouse osteoblast-like cells-modulation by changes in receptor level. J Cell Physiol 126:21-28
30. 3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. Endocrinology 136:705-712
31. 31. Mora GR, Mahesh VB 1996 Autoregulation of androgen receptor in rat ventral prostate: involvement of c-fos as a negative regulator. Mol Cell Endocrinol 124:111-120
32. 32. Radwan F, Leger F, Carmel M, Elhilali M, Lehoux J-G 1986 Characterization of androgen receptors in normal and malignant human prostatic tissues. Prostate 9:147-158
33. 33. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ 1995 Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 136:2172-2178
34. 34. Tetsuka M, Hillier SG 1996 Androgen receptor gene expression in rat granulosa cells: the role of follicle-stimulating hormone and steroid hormones. Endocrinology 137:4392-4397
35. 35. Shen R, Lin MC, Sadeghi F, Swerdloff RS, Rajfer J, Gonzalez-Cadavid NF 1996 Androgens are not major down-regulators of androgen receptor levels during growth of the immature rat penis [published erratum appears in J Steroid Biochem Mol Biol 58:137]. J Steroid Biochem Mol Biol 57:301-313
36. 36. Stubbs AP, Lalani EN, Stamp GW, Hurst H, Abel P, Waxman J 1996 Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC-3 and DU-145. FEBS Lett 383:237-240
37. 37. DeFranco DB, Ramakrishnan C, Tang Y 1998 Molecular chaperones and subcellular trafficking of steroid receptors. J Steroid Biochem Mol Biol 65:51-58
38. 38. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803
39. 39. Kokontis J, Takakura K, Hay N, Liao S 1994 Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573
40. 40. Umekita Y, Hiipakka RA, Kokontis JM, Liao S 1996 Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93:11802-11807
41. kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12:941-953
42. 42. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A 1993 Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA [published erratum appears in Cancer Res 55:719]. Cancer Res 53:1304-1311
43. 43. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW 1996 Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93:15152-15157